Vicapsys Life Sciences, Inc. (VICP)
1.00
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Vicapsys Life Sciences Research and Development Expense (Quarterly) : 0.00 for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.00 |
| March 31, 2025 | 0.0006M |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.0037M |
| June 30, 2024 | 0.01M |
| March 31, 2024 | 0.0003M |
| December 31, 2023 | |
| September 30, 2023 | 0.0033M |
| June 30, 2023 | 0.002M |
| March 31, 2023 | 0.01M |
| December 31, 2022 | |
| September 30, 2022 | 0.0031M |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.01M |
| December 31, 2021 | 0.0105M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.0049M |
| March 31, 2021 | 0.0023M |
| December 31, 2020 | 0.0081M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.094M |
| December 31, 2019 | |
| June 30, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |
| Sangamo Therapeutics, Inc. | 26.57M |
| Sarepta Therapeutics, Inc. | 91.26M |
| Anixa Biosciences, Inc. | 1.258M |